Cargando…

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

OBJECTIVE: We investigated the determinants and clinical correlations of MRI-detected brain volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase 3 trials of fingolimod: FREEDOMS, FREEDOMS II, and TRANSFORMS. METHODS: Post hoc analyses were conducted in the inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radue, Ernst-Wilhelm, Barkhof, Frederik, Kappos, Ludwig, Sprenger, Till, Häring, Dieter A., de Vera, Ana, von Rosenstiel, Philipp, Bright, Jeremy R., Francis, Gordon, Cohen, Jeffrey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339126/ https://www.ncbi.nlm.nih.gov/pubmed/25632085 http://dx.doi.org/10.1212/WNL.0000000000001281

Ejemplares similares

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
por: Sprenger, Till, et al.
Publicado: (2019)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
por: Kappos, Ludwig, et al.
Publicado: (2015)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression
por: Nakamura, Yuri, et al.
Publicado: (2018)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
por: Amann, Michael, et al.
Publicado: (2014)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
por: Sprenger, Till, et al.
Publicado: (2022)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis
por: Rahmanzadeh, Reza, et al.
Publicado: (2022)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
por: Mattiesing, Rozemarijn M., et al.
Publicado: (2022)

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
por: Disanto, Giulio, et al.
Publicado: (2016)

A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects
por: Rahmanzadeh, Reza, et al.
Publicado: (2022)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging
por: Rahmanzadeh, Reza, et al.
Publicado: (2021)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
por: Constantinescu, Cris S., et al.
Publicado: (2015)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES
por: Filippi, M., et al.
Publicado: (2016)

Age of second language acquisition in multilinguals has an impact on gray matter volume in language-associated brain areas
por: Kaiser, Anelis, et al.
Publicado: (2015)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

Making better use of our brain MRI research data
por: Barkhof, Frederik
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_m7penlaqj4vohkjcf8prn10cta